Cohance Lifesciences says it will invest $18 million in NJ Bio and Aruka Bio. The move is intended to expand Cohance’s end-to-end CRDMO capabilities, bringing together research, manufacturing, and next-generation ADC (antibody-drug conjugate) capabilities under one operating umbrella.
Business Line frames the investment as strengthening Cohance’s broader CRDMO offering, highlighting integration of research and manufacturing functions. The Hindu adds that the funding supports deeper integration of NJ Bio’s customer-facing services and a focused development push for Aruka’s proprietary pipeline, including through potential partnerships. Both transactions are described as being funded through Cohance’s internal accruals, with the primary stated goal being to sharpen focus on ADC-related development and execution.
